Clinical Aspects of Atherosclerotic-Carcinogenesis Hypothesis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancers
- Sponsor
- Sakakibara Heart Institute
- Enrollment
- 8856
- Primary Endpoint
- inicidence of cancers
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
As previously reported (IJC Heart & Vasculature 2017; 17: 11.), our epidemiological analysis showing high incidence of cancers in patients with atherosclerotic cardiovascular diseases as compared with those with non-atherosclerotic cardiovascular diseases may imply a clinical possibility of a role of atherosclerosis in cancer developments. In the present study, to address our hypothesis that cancer developments may come with a strength of atherosclerosis, we traced an incidence of cancers in a total of 8,856 patients with coronary artery diseases (CAD) for a median follow-up of 1,095 days (interquartile range, 719-1,469 days) using the Sakakibara Health Integrative Profile (SHIP) database.
Detailed Description
In accordance with a presence or absence of poly-arterial diseases such as aortic and/or peripheral artery diseases as an indicator of a strength of atherosclerosis, an incidence of cancers and all-cause death in two cohorts of 8,140 patients with CAD-only and 716 with CAD with poly-arterial diseases were evaluated to track an incidence of cancers and ali-cause mortality during median follou-up periods of 3 to 4 years.
Investigators
Makoto Suzuki
Director, Department of Cardiology
Sakakibara Heart Institute
Eligibility Criteria
Inclusion Criteria
- •patients with diagnosed coronary artery diseases without a dignosis of cancers at the entry of SHIP between January 2009 and July 2014.
Exclusion Criteria
- •patients with diagnosed coronary artery diseases who had already been diagnosed with any cancers at the time of enrollment in the SHIP, and who were not followed-up after the entry of SHIP.
Outcomes
Primary Outcomes
inicidence of cancers
Time Frame: through study completion, an average of 3 years
number of all types of cancers during follow-up periods
Secondary Outcomes
- all-cause mortality(through study completion, an average of 3 years)